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IMPORTANCE Blood pressure (BP) is a known risk factor for overall mortality and
cardiovascular (CV)-specific fatal and nonfatal outcomes. It is uncertain which BP index
is most strongly associated with these outcomes.
OBJECTIVE To evaluate the association of BP indexes with death and a composite CV event.
DESIGN, SETTING, AND PARTICIPANTS Longitudinal population-based cohort study of 11 135
adults from Europe, Asia, and South America with baseline observations collected from
May 1988 toMay 2010 (last follow-ups, August 2006-October 2016).
EXPOSURES Blood pressure measured by an observer or an automated office machine;
measured for 24 hours, during the day or the night; and the dipping ratio (nighttime divided
by daytime readings).
MAIN OUTCOMES ANDMEASURES Multivariable-adjusted hazard ratios (HRs) expressed the
risk of death or a CV event associated with BP increments of 20/10mmHg. Cardiovascular
events included CVmortality combined with nonfatal coronary events, heart failure,
and stroke. Improvement in model performance was assessed by the change in the area
under the curve (AUC).
RESULTS Among 11 135 participants (median age, 54.7 years, 49.3%women), 2836
participants died (18.5 per 1000 person-years) and 2049 (13.4 per 1000 person-years)
experienced a CV event over a median of 13.8 years of follow-up. Both end points were
significantly associated with all single systolic BP indexes (P < .001). For nighttime systolic BP
level, the HR for total mortality was 1.23 (95% CI, 1.17-1.28) and for CV events, 1.36 (95% CI,
1.30-1.43). For the 24-hour systolic BP level, the HR for total mortality was 1.22 (95% CI,
1.16-1.28) and for CV events, 1.45 (95% CI, 1.37-1.54). With adjustment for any of the other
systolic BP indexes, the associations of nighttime and 24-hour systolic BP with the primary
outcomes remained statistically significant (HRs ranging from 1.17 [95% CI, 1.10-1.25] to 1.87
[95% CI, 1.62-2.16]). Base models that included single systolic BP indexes yielded an AUC of
0.83 for mortality and 0.84 for the CV outcomes. Adding 24-hour or nighttime systolic BP to
basemodels that included other BP indexes resulted in incremental improvements in the
AUC of 0.0013 to 0.0027 for mortality and 0.0031 to 0.0075 for the composite CV outcome.
Adding any systolic BP index tomodels already including nighttime or 24-hour systolic BP did
not significantly improvemodel performance. These findings were consistent for diastolic BP.
CONCLUSIONS AND RELEVANCE In this population-based cohort study, higher 24-hour and
nighttime blood pressure measurements were significantly associated with greater risks
of death and a composite CV outcome, even after adjusting for other office-based or
ambulatory blood pressure measurements. Thus, 24-hour and nighttime blood pressure may
be considered optimal measurements for estimating CV risk, although statistically, model
improvement compared with other blood pressure indexes was small.
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N orthAmerican,1,2European,3,4 Japanese,5andChinese6guidelines unanimously recommend ambulatoryblood pressure (BP) monitoring for BP assessment.
However, which BP index among the multitude of measure-
ments that can be derived from conventional and ambula-
tory BP recordings is more closely associated with adverse
health outcomes remains unresolved. In several studies, the
association between cardiovascular risk and BP was stron-
gest for systolic readings taken at nighttime,7 an observation
subsequently replicated among patients with hypertension8
or referred for ambulatoryBPmonitoring.9More recently,10BP
readings via automatedofficemachineswas introduced as an
alternative to ambulatory monitoring, but the strength of its
associationwith a cardiovascular outcome isunknown.Given
the uncertainty left by these previous findings,7-13 the objec-
tive of this studywas to evaluate various typesofBPmeasure-
ments and assess the strength of their associationswithmor-
tality and adverse cardiovascular outcomes.
Methods
Study Participants
All population studies included in the International Database
on Ambulatory Blood Pressure in Relation to Cardiovascular
Outcome (IDACO)14 receivedethical approval fromthe respon-
sible institutional reviewboards in their country of origin and
adhered to theprinciples of theDeclarationofHelsinki.15 Par-
ticipants provided written informed consent. The IDACO da-
tabase was constructed and is regularly updated at the Stud-
ies Coordinating Centre in Leuven, but does not include any
data allowing identification of study participants. In accor-
dancewith current national regulations, reviewboards either
waivedorprovidedethical clearance for secondaryuseofdata
to be included in the IDACO resource.
Population studies qualified for inclusion if office and the
ambulatoryBPmeasures and cardiovascular risk factorswere
available at baseline and if follow-up included both fatal and
nonfatal outcomes. The Expanded eMethods section and
eTable 1 in Supplement 1 provide detailed information on the
population sampling methods, timelines, and country of re-
cruitment. Across all studies, enrollment took place from
August 1985untilMay2010 (eTable 1 in Supplement 1). For the
current study, baseline refers to the first measurement of the
conventional and theambulatoryBPmeasures alongwith car-
diovascular risk factors (May 1988 until May 2010); timing of
the last follow-up ranged from August 2006 to October 2016
across studies. References specifying methods in each of the
13 cohorts are available in the Expanded eMethods section in
Supplement 1.
BPMeasurement
Nurses or physicians obtained the conventional readings
with a standard mercury sphygmomanometer or with vali-
dated auscultatory or oscillometric devices. Patients were
considered to have hypertension if their conventional BP
was 140/90 mm Hg or higher or if they were taking antihy-
pertensive drugs.
For ambulatory monitoring (eTable 2 in Supplement 1),
portable monitors were programmed to obtain ambulatory
readings at 30-minute intervals throughout the whole day or
at intervals of 15 to 30 minutes during daytime and at inter-
vals ranging from 20 to 60 minutes during the nighttime.16
Daytime readings ranged from 10 AM to 8 PM in European and
South American countries and from 8 AM to 6 PM in Asian
countries. The corresponding nighttime intervals ranged
from midnight to 6 AM in European and South American
countries and from 10 PM to 4 AM in Asian countries. For
analysis, ambulatory recordings had to include at least 6 day-
time and 3 nighttime readings.17 We used the mean BP
recordings taken by automated devices during the first hour
patients were being monitored while in a medical environ-
ment. The dipping ratio was calculated by dividing the night-
time by the daytime BP level. We focused on systolic BP,
because it is the predominant risk factor among older adults
and because the mean age of patients in this study was 53.4
years.18 Diastolic BP was analyzed to replicate findings
for systolic BP. In categorical analyses, the dipping ratios
were 0.80 or less for extreme dipping, more than 0.80 to
0.90or less for normal dipping,more than0.90 to 1.00or less
for nondipping, andmore than 1.00 for reversedipping.19 The
ExpandedMethods section in Supplement 1 describes the col-
lection of questionnaire and biochemical data.
Ascertainment of End Points
We ascertained vital status and the incidence of fatal and
nonfatal events from the appropriate sources in each
country.14 All events were prespecified and coded according
to the International Classification of Diseases (ICD).14 The
coprimary end points were total mortality and a composite
cardiovascular event consisting of cardiovascular mortality
combined with nonfatal coronary events, heart failure, and
stroke. Secondary end points included cardiovascular mor-
tality (ICD-8, 390-448; ICD-9, 390.0-459.9; and ICD-10, I00-
I79 and R96), coronary events (death from ischemic heart
disease [ICD-8, 411-412; ICD-9, 411 and 414; and ICD-10, I20
and I24-I25], sudden death [ICD-8, 427.2 and 795; ICD-9,
427.5 and 798; and ICD-10, I46 and R96], nonfatal myocar-
dial infarction [ICD-8 or ICD-9, 410 and ICD-10, I21-I22], and
Key Points
Question What is the association of office and ambulatory blood
pressure with subsequent risk of mortality and cardiovascular
outcomes?
Findings In a population-based cohort of 11 135 adults, higher
24-hour and nighttime blood pressure readings were significantly
associated with greater risks of death and cardiovascular events
that included cardiovascular mortality combined with nonfatal
coronary events, heart failure, or stroke. This association persisted
after adjusting for other blood pressure measurements taken
during an office visit or during ambulatory monitoring.
Meaning Higher 24-hour and nighttime blood pressure readings
were significantly associated with greater risks of death and a
composite of cardiovascular outcomes, although statistically the
incremental model improvement was small.
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coronary revascularization), and stroke (ICD-8 or ICD-9,
430-434 and 436; and ICD-10, I60-I64 and I67-I68), not
including transient ischemic attack. Heart failure (ICD-8,
427.0, 427.1, 427.2, 428, 429, 519.1, and 782.4, ICD-9, 429,
and ICD-10, I50 and J81) was included in the composite car-
diovascular outcome. Its diagnosis required hospitalization
in the Scandinavian cohorts.20,21 In the other cohorts, heart
failure was either a clinical diagnosis or the diagnosis on the
death certificate. All outcomes were validated against hos-
pital files or medical records held by primary care physi-
cians or specialists. In all outcome analyses, we only consid-
ered the first event within each category. No participant was
lost to follow-up.
Statistical Analysis
Weapplied theKolmogorov-Smirnov test for assessing thenor-
mality of distributions. For comparison ofmeans andpropor-
tions,weapplied the large-sampleZ test andFisher exact test,
respectively. After stratification for cohort and sex, we inter-
polatedmissing values of bodymass index and serumcholes-
terol levels from the regression slopes on age. In participants
with unknown status of smoking, drinking, antihypertensive
treatment, diabetes mellitus, or unknown history of cardio-
vascular disease,we set the indicator (dummy) variable to the
cohort- and sex-specific mean of the codes (0, 1).
We compared the cumulative incidence of the primary
and secondary outcomes by dipping status, while adjusting
for sex and age, and next for the 24-hour or nighttime BP.
Inmultivariable-adjustedCox regression,weaccounted for co-
hort (randomeffect), sex, andbaseline characteristics includ-
ing age, body mass index, smoking and drinking status, se-
rumcholesterol level, antihypertensivedrug intake, historyof
cardiovascular disease, and diabetes mellitus. We expressed
hazard ratios (HRs) per increments of 20/10 mm Hg BP and
per 0.10-increment in the dipping ratio. In models including
2 BP indexes, we uncorrelated these indexes by regressing
one index on the other and using the residual of one index in
computing the HRs or in assessing improvement of model
performance.22Weconstructedheatmaps tovisualize thecon-
tribution of the 24-hour and nighttime BP measurements in
their associations with outcomes. To adjust for cohort, we
pooledparticipants recruited in the frameworkof theEuropean
ProjectonGenes inHypertension,Novosibirsk,Russia;Kraków
andGdańsk, Poland; Pilsen, the Czech Republic; and Padova,
Italy.23 We checked the proportional hazards assumption
by theKolmogorov-type supremumtest andby testing the in-
teraction between follow-up duration and the BP variables.
Sensitivity analyses addressed the use of antihypertensive
drug at baseline, the consistency of the results based on a di-
ary approach todefinewakefulness and sleep, and theweight
of cohorts in theoverall pooled results. Improvement inmodel
performancewas assessed from change in the area under the
curve (AUC).
Dipping status as a categorical variablewasanalyzedusing
thedeviation frommeancoding,24whichcontrasts risk ineach
group to the average risk in the whole study population and
whichallowscomputingconfidence intervals for theHRineach
group without the need to define a reference group. We did
not apply a correction for multiple testing because the out-
comes inour studywerehighly correlated so that each test did
not provide an independent opportunity for a type I error.25
Thus, the analyses of secondary outcomes should be consid-
ered as exploratory. For databasemanagement and statistical
analysis,weusedSASsoftware, version9.4,maintenance level
5. Statistical significance was a 2-tailed α of ≤.05.
Results
Baseline Characteristics of Participants
Of 13 111 people included in the database, we excluded 1976
because they were adolescents without events (n = 493) or
because they had an ambulatory BP recording with fewer
than 6 daytime or 3 nighttime readings (n = 1483). The study
population analyzed statistically (n = 11 135) included 5494
women (49.3%) and consisted of 6929 white Europeans
(62.2%), 1887 Asians (17.0%), and 2319 South Americans
(20.8%). Missing values were interpolated for body mass
index (n = 33), serum cholesterol level (n = 806), smoking
status (n = 56), drinking status (n = 805), antihypertensive
treatment (n = 16), diabetes mellitus (n = 5), and history of
cardiovascular disease (n = 1).
Themedianageat enrollmentwas54.7years (Table 1). The
study population included 3022 smokers (27.3%) and 5185
participants (56.3%) reporting alcohol consumption. Of 4866
participants (43.7%) with hypertension on conventional BP
measurement,2262 (46.5%)were takingantihypertensivedrug
treatment. A total of 849participants (7.6%)haddiabetes and
1291 (11.6%)hadahistoryof cardiovasculardisease.Therewere
9286 participants (83.4%) with 3 automated office BP moni-
toring readings, 1650 (14.8%)with2, and 199 (1.8%)with 1.The
mediannumber of ambulatory readingswas 55 (5th-95thper-
centile intervals, 33-82) for 24-hours, 28 (5th-95th percentile
intervals, 14-41) for daytime, and 11 (5th-95th percentile in-
terval, 5-13) for nighttime readings. eTable 3 in Supplement 1
shows that all BP indexes were highly correlated.
Primary End Points
Incidence of Outcomes
Among11 135participants, themedian follow-upwas 13.8years
(5th-95th percentile interval, 2.5-25.1 years). Across cohorts
(eTable 1 in Supplement 1), themedian follow-up ranged from
2.4 years (5th-95th percentile interval, 2.3-2.6 years) to 22.8
years (5th-95th percentile interval, 11.1-26.2 years). During
153 140person-yearsof follow-up, 2836participantsdied (18.5
per 1000person-years) and2049experiencedacomposite car-
diovascular event (13.4 per 1000 person-years). eTable 4 in
Supplement 1 lists the number of events by category.
Cox Regression
In all outcome analyses that follow, the proportional hazard
assumptionwas not violated and the residualmethod, as de-
scribed in the Statistical Analysis section, was used. None of
the interaction termsbetweenaBP indexunder studywithany
residual of a comparator index reached statistical signifi-
cance (P > .09).
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In analyses adjusted for cohort, sex, age, body mass
index, smoking and drinking status, serum cholesterol lev-
els, antihypertensive drug treatment use, history of cardio-
vascular disease and diabetes mellitus (Table 2), the associa-
tion between systolic BP and the primary outcomes were
all statistically significant (P < .001). Adjusting for 24-hour
systolic BP, the HR for the nighttime systolic BP readings
for total mortality was 1.24 (95% CI, 1.14-1.36), and for all
cardiovascular events, the HR was 1.16 (95% CI, 1.05-1.28;
Table 2). Adjusting for 24-hour BP readings, the HR for
systolic dipping for total mortality was 1.11 (95% CI,
1.06-1.15), and for all cardiovascular outcomes, it was 1.08
(95% CI, 1.03-1.13; Table 2). After adjusting for the nighttime
systolic BP, only conventional systolic BP readings was asso-
ciated with total mortality (HR, 1.05; CI, 1.01 to 1.10;
P = .02). Adjustment for the nighttime systolic BP did not
Table 1. Baseline Characteristics of Participants
Characteristics Participants
No. of participants 11 135
Sex, No. (%)
Men 5641 (50.7)
Women 5494 (49.3)
Region of enrollment, No. (%)a
Europe 6929 (62.2)
Asia 1887 (17.0)
South America 2319 (20.8)
Current smoking, No./total (%)b,c 3022/11 079 (27.3)
Drinking alcohol, No./total (%)b,d 5815/10 330 (56.3)
Risk factors, No./total (%)
Hypertensionb,e 4866 (43.7)
Antihypertensive treatmentb 2262/11 117 (20.3)
Diabetes mellitusb,f 849/11 130 (7.6)
History of CVDa 1291/11 134 (11.6)
Dipping status, No. (%)b,g
Extreme 2018 (18.1)
Normal 5617 (50.4)
None 2809 (25.2)
Reverse 691 (6.2)
Age, median (IQR), y 54.7 (41.6-67.3)
BMI, mean (SD) 25.5 (4.4)
No. 11 102
Serum cholesterol, mean (SD), mg/dL 216.3 (45.2)
No. 10 329
Blood pressure, mm Hgh
Conventional
Systolic/diastolic, mean 132.4/79.8
SD 23.0/11.8
Automated office
Systolic/diastolic, mean 135.3/82.3
SD 20.0/11.7
24 hours
Systolic/diastolic, mean 123.6/73.7
SD 14.3/8.5
Daytime
Systolic/diastolic, mean 129.7/78.7
SD 15.2/9.2
Nighttime
Systolic/diastolic, mean 112.6/64.7
SD 15.5/9.4
Dipping ratioi
Systolic/diastolic, mean 0.87/0.83
SD 0.08/0.06
Abbreviations: BMI, bodymass
index, calculated as weight in
kilograms divided by height in
meters squared; BP, blood pressure;
CVD, cardiovascular disease;
IQR, interquartile range.
SI conversion factor: to convert
cholesterol frommg/dL tommol/L,
multiply by 0.0259; glucose from
mg/dL tommol/L, multiply by
0.0555.
a Details provided in eTable 1 in
Supplement 1.
bAssessed only at baseline.
c Use of smokingmaterials on
a daily basis.
dDrinking was an average alcohol
intake of 5 g or more per day.
e A conventional BP of 140/90mmHg
or higher or use of antihypertensive
drugs.
f Use of antidiabetic drugs,
fasting blood glucose of 126mg/dL
or higher, random blood glucose
of 200mg/dL or higher,
a self-reported diagnosis, or
diabetes documented in practice or
hospital records.
g Categorization in extreme dippers
(0.80), normal dippers (>0.80 to
0.90), nondippers (>0.90 to
1.00), and reverse dippers
(>1.00) was based on the systolic
dipping ratio.
h Conventional BP wasmeasured
using a standardmercury
sphygmomanometer or validated
auscultatory or oscillometric
devices. Automated BPwas the
average of the ambulatory
recordings during the first recording
hour, when themonitors were
applied in a medical environment.
Mean BP levels over the whole
day and during day/night
(10 AM to 8 PM/midnight to 6 AM
for Europeans and South Americans
and 8 AM to 6 PM/10 PM to 4 AM
in Asians).
i The dipping ratio was nighttime
divided by daytime BP.
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Table 2. Association of OutcomesWith Systolic BP IndexesWithout orWith Adjustment for 24-Hour or Nighttime Systolic BPa
Outcomes
Adjusted
Additionally Adjusted Systolic BPb
24 Hours Nighttime
Hazard Ratio (95% CI)c P Value
Hazard Ratio
(95% CI)c P Value
Hazard Ratio
(95% CI)c P Value
Total Mortality (n = 2836)
Systolic BP index
Conventional 1.12 (1.08-1.17) <.001 1.05 (1.01-1.10) .03 1.05 (1.01-1.10) .02
Automated office systolic BP 1.08 (1.04-1.12) <.001 0.97 (0.92-1.02) .23 1.00 (0.96-1.05) .94
Measure times
24 hours 1.22 (1.16-1.28) <.001 NA NA 0.98 (0.88-1.08) .68
Daytime 1.14 (1.09-1.20) <.001 0.78 (0.69-0.88) <.001 0.98 (0.92-1.05) .64
Nighttime 1.23 (1.17-1.28) <.001 1.24 (1.14-1.36) <.001 NA NA
Dipping ratiod 1.13 (1.09-1.18) <.001 1.11 (1.06-1.15) <.001 1.02 (0.97-1.07) .46
All Cardiovascular Outcomes (n = 2049)
Systolic BP index
Conventional 1.20 (1.15-1.26) <.001 1.05 (1.00-1.11) .06 1.09 (1.04-1.14) .001
Automated office 1.19 (1.14-1.24) <.001 0.98 (0.93-1.04) .58 1.07 (1.02-1.12) .007
Measure times
24 hours 1.45 (1.37-1.54) <.001 NA NA 1.25 (1.11-1.41) <.001
Daytime 1.33 (1.26-1.41) <.001 0.77 (0.67-0.89) <.001 1.11 (1.03-1.20) .005
Nighttime 1.36 (1.30-1.43) <.001 1.16 (1.05-1.28) .004 NA NA
Dipping ratiod 1.14 (1.08-1.19) <.001 1.08 (1.03-1.13) <.001 0.92 (0.87-0.98) .008
Cardiovascular Mortality (n = 1073)
Systolic BP index
Conventional 1.22 (1.15-1.29) <.001 1.07 (1.00-1.15) .06 1.09 (1.02-1.17) .008
Automated office 1.19 (1.12-1.26) <.001 0.97 (0.90-1.05) .44 1.05 (0.98-1.12) .14
Measure times
24 hours 1.48 (1.36-1.60) <.001 NA NA 1.17 (1.00-1.37) .06
Daytime 1.34 (1.24-1.45) <.001 0.75 (0.62-0.91) .003 1.09 (0.98-1.20) .10
Nighttime 1.41 (1.32-1.50) <.001 1.26 (1.10-1.44) <.001 NA NA
Dipping ratiod 1.17 (1.10-1.25) <.001 1.12 (1.05-1.19) <.001 0.95 (0.88-1.03) .18
Coronary Outcomes (n = 922)
Systolic BP index
Conventional 1.14 (1.07-1.22) <.001 1.01 (0.94-1.10) .72 1.04 (0.97-1.12) .30
Automated office 1.18 (1.11-1.26) <.001 1.04 (0.95-1.13) .41 1.08 (1.00-1.16) .04
Measure times
24 hours 1.35 (1.24-1.47) <.001 NA NA 1.12 (0.94-1.34) .22
Daytime 1.27 (1.16-1.38) <.001 0.83 (0.67-1.03) .09 1.07 (0.96-1.20) .23
Nighttime 1.30 (1.21-1.40) <.001 1.20 (1.03-1.40) .02 NA NA
Dipping ratiod 1.13 (1.05-1.21) <.001 1.09 (1.01-1.17) .02 0.95 (0.87-1.04) .30
Stroke (n = 822)
Systolic BP index
Conventional 1.30 (1.21-1.40) <.001 1.11 (1.02-1.21) .02 1.16 (1.07-1.26) <.001
Automated office 1.24 (1.16-1.33) <.001 0.99 (0.90-1.08) .76 1.10 (1.02-1.19) .01
Measure times
24 hours 1.60 (1.46-1.76) <.001 NA NA 1.36 (1.14-1.63) .001
Daytime 1.45 (1.33-1.58) <.001 0.80 (0.65-1.00) .05 1.19 (1.06-1.33) .003
Nighttime 1.46 (1.36-1.58) <.001 1.17 (1.01-1.36) .04 NA NA
Dipping ratiod 1.14 (1.06-1.23) <.001 1.08 (1.01-1.16) .03 0.87 (0.80-0.96) .004
Abbreviations: BP, blood pressure; NA, not applicable.
a All models accounted for cohort, sex, age, bodymass index, smoking and
drinking, serum cholesterol, antihypertensive drug intake, history of
cardiovascular disease, and diabetes mellitus.
bModels including 2 correlated systolic BP indexes were constructed, using the
residual method (see Statistical Analysis section).
c Hazard ratios express the risk for increments of 20mmHg in systolic BP and
0.10 in the dipping ratio.
d The dipping ratio is calculated by dividing nighttime by daytime systolic BP.
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remove the statistical significance of the association of the
conventional or automated office systolic BP or with the
daytime or 24-hour systolic BP with the composite cardio-
vascular outcomes.
In models including both nighttime and 24-hour systolic
BP (Table 3), the HRs for 24-hour measures were 0.98 (95%
CI, 0.88-1.08) for total mortality and 1.25 (95% CI, 1.11-1.41)
for the composite cardiovascular outcomes. In models that
adjusted for a systolic BP index different from the nighttime
systolic BP (Table 3), the HRs expressing the association of
the 24-hour systolic BP with the coprimary outcomes ranged
from 1.17 (95% CI, 1.10-1.25) to 1.87 (95% CI, 1.62-2.16). After
adjusting for each of the other systolic BP indexes (Table 3),
the HRs expressing the association of nighttime systolic BP
with the coprimary outcomes ranged from 1.16 (95% CI, 1.05-
1.28) to 1.44 (95% CI, 1.35-1.54).
Table 3. Association of OutcomesWith 24Hours or Nighttime Systolic Blood Pressure
Adjusted for Other Systolic Blood Pressure Indexes
Systolic BP Indexes
Systolic BPa
24 Hours Nighttime
Hazard Ratio
(95% CI)b P Value
Hazard Ratio
(95% CI)b P Value
Total Mortality (n = 2836)
Conventional systolic BP 1.17 (1.10-1.25) <.001 1.20 (1.14-1.26) <.001
Automated office systolic BP 1.25 (1.17-1.34) <.001 1.22 (1.17-1.29) <.001
Systolic BP
24 hours NA NA 1.24 (1.14-1.36) <.001
Daytime 1.55 (1.36-1.77) <.001 1.24 (1.17-1.31) <.001
Nighttime 0.98 (0.88-1.08) .68 NA NA
Dipping ratioc 1.19 (1.13-1.26) <.001 1.21 (1.14-1.28) <.001
All Cardiovascular Outcomes (n = 2049)
Conventional systolic BP 1.40 (1.31-1.50) <.001 1.31 (1.24-1.38) <.001
Automated office systolic BP 1.47 (1.36-1.59) <.001 1.32 (1.25-1.40) <.001
Systolic BP
24 hours NA NA 1.16 (1.05-1.28) .004
Daytime 1.87 (1.62-2.16) <.001 1.29 (1.21-1.37) <.001
Nighttime 1.25 (1.11-1.41) <.001 NA NA
Dipping ratioc 1.43 (1.34-1.51) <.001 1.44 (1.35-1.54) <.001
Cardiovascular Mortality (n = 1073)
Conventional systolic BP 1.41 (1.28-1.55) <.001 1.35 (1.26-1.45) <.001
Automated office systolic BP 1.52 (1.37-1.68) <.001 1.38 (1.28-1.48) <.001
Systolic BP
24 hours NA NA 1.26 (1.10-1.44) <.001
Daytime 1.95 (1.60-2.38) <.001 1.34 (1.23-1.47) <.001
Nighttime 1.17 (1.00-1.37) .06 NA NA
Dipping ratioc 1.44 (1.33-1.56) <.001 1.46 (1.34-1.59) <.001
Coronary Outcomes (n = 922)
Conventional systolic BP 1.33 (1.20-1.48) <.001 1.28 (1.18-1.39) <.001
Automated office systolic BP 1.30 (1.16-1.47) <.001 1.25 (1.15-1.36) <.001
Systolic BP
24 h NA NA 1.20 (1.03-1.40) .02
Daytime 1.62 (1.29-2.03) <.001 1.25 (1.13-1.38) <.001
Nighttime 1.12 (0.94-1.34) .22 NA NA
Dipping ratioc 1.32 (1.21-1.44) <.001 1.35 (1.23-1.48) <.001
Stroke (n = 822)
Conventional systolic BP 1.50 (1.34-1.67) <.001 1.37 (1.26-1.49) <.001
Automated office systolic BP 1.62 (1.44-1.83) <.001 1.40 (1.29-1.53) <.001
Systolic BP
24 hours NA NA 1.17 (1.01-1.36) .04
Daytime 1.98 (1.58-2.47) <.001 1.34 (1.21-1.47) <.001
Nighttime 1.36 (1.14-1.63) .001 NA NA
Dipping ratioc 1.57 (1.43-1.73) <.001 1.61 (1.46-1.78) <.001
Abbreviations: BP, blood pressure;
NA, not applicable.
a All models accounted for cohort,
sex, age, bodymass index, smoking
and drinking, serum cholesterol,
antihypertensive drug intake,
history of cardiovascular disease
and diabetes mellitus and were
constructed, using the residual
method (see the Statistical Analysis
section).
bHazard ratios express the risk for
increments of 20mmHg in SBP and
0.10 in the dipping ratio.
c The dipping ratio is calculated by
dividing nighttime by daytime
systolic BP.
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Sensitivity Analyses
Theaforementioned findingsweregenerally consistent fordia-
stolic BP (eTables 5 and 6 in Supplement 1) and in sensitivity
analyses—from which 2262 participants (20.3%) taking anti-
hypertensive drug medication at baseline were excluded
(eTables 7and8 inSupplement 1)—when thediarymethodwas
applied to 7133participants (64.1%) todefineperiods ofwake-
fulness and sleep (eTables 9 and 10 in Supplement 1), orwhen
cohorts were excluded (eTable 11 in Supplement 1).
Improvement inModel Performance
Based on the results presented in Table 2 and Table 3 for sys-
tolic BP and in eTables 5 and 6 in Supplement 1 for diastolic
BP, of 30 possible permutations to compare 2 BP indexes, the
24-hour andnighttimemeasureswere carried forward in fur-
ther analyses to study improvement in model performance.
Heatmaps for systolic BP (Figure 1) showed that along the
vertical axis the 10-year risks of both primary outcomeswere
significantly greater with higher nighttime systolic BP read-
ings (P ≤ .03), but that along the horizontal axis, the risk of
death was not significantly associated with the 24-hour sys-
tolic BP (P = .66). Heat maps for diastolic BP were confirma-
tory (eFigure 1 in Supplement 1).
In general, adding the 24-hour or nighttime systolic BP
(eTable 12 in Supplement 1), or adding 24-hour or nighttime
diastolic BP (eTable 13 in Supplement 1) to models including
any other systolic or diastolic BP index significantly im-
provedmodel performance. Basemodels that included single
systolic BP indexes yielded an AUC of 0.83 for mortality and
0.84 for the cardiovascular outcomes, and adding 24-hour or
nighttime systolic BP to base models that included other BP
indexes resulted in incremental improvements in AUC of
0.0013 to 0.0027 for total mortality and 0.0031 to 0.0075 for
the composite cardiovascular outcome. Adding 24-hour sys-
tolic BP to nighttime systolic BP did not significantly improve
model performance (eTable 12 in Supplement 1) with similar
findings for 24-hour diastolic BP plus nighttime diastolic BP
(eTable 13 in Supplement 1). Conversely, nighttime systolic or
diastolic BP added to 24-hour systolic or diastolic BP im-
proved model performance for the estimation of the 10-year
risk of death; the change in the AUC was 0.0013 (95% CI,
0.0001-0.0024) systolic and 0.0012 (95% CI, 0.0002-
0.0022)diastolic.Modelperformancewasnot significantly im-
provedbyaddinganyother systolic ordiastolicBP index to24-
hourornighttimemeasures (eTables 14and15 inSupplement 1)
Dipping as Categorical Variable
Based on systolic BP, the study included 2018 extreme dip-
pers (18.1%), 5617 dippers (50.4%), 2809nondippers (25.2%),
and691 reverse dippers (6.2%).Figure 2AandB show the sex-
and age-adjusted cumulative incidence of totalmortality and
cardiovascular outcomes bydipping status. The sex- and age-
adjustedcumulative incidence significantlydiffered (P < .001)
according to dipping status with the highest rates in reverse
dippers and the lowest rates in extremedippers. For totalmor-
tality, the cumulative 10-year incidence amounted to 3.73%
(95% CI, 3.3%-4.16%) for extreme dippers, 4.08% (95% CI,
3.69%-4.47%) in normal dippers, 4.62% (95% CI, 4.13%-
5.12%) innondippers, and5.74% (95%CI, 4.92%-6.55%) in re-
versedippers; for thecompositecardiovascularoutcome, these
rateswere4.76%(95%CI,4.16%-5.34%),5.27%(95%CI,4.77%-
5.78%), 5.87% (95% CI, 5.21%-6.53%), and 7.77% (95% CI,
6.57%-8.95%), respectively.Thedifference in the sex- andage-
adjusted 10-year cumulative incidence between extreme and
reversedipperswas2.01% (95%CI, 1.08%-2.93%;P < .001) for
totalmortality and 3.02% (95%CI, 1.69%-4.34%;P < .001) for
the composite cardiovascular outcome.
Additional adjustment for the nighttime systolic BP at-
tenuated thesedifferences to0.33% (95%CI, −0.53%to 1.18%;
P = .46) and –0.71% (95%CI, −1.83% to0.41%;P = .21), respec-
tively (Figure 2E and F), whereas these differences retained
significancewhenadjusted for24-hoursystolicBP: 1.62%(95%
CI, 0.74% to 2.50%; P < .001) for total mortality and 2.00%
(95% CI, 0.80% to 3.19%; P = .001) for the composite cardio-
vascular outcome (Figure 2C and D).
Secondary Outcomes
During follow-up, cardiovascularmortality accounted for 1073
deaths (7.0 per 1000 person-years). Coronary events oc-
curred in922participants (6.0per 1000person-years) and822
(5.4 per 1000 person-years) had a stroke (eTable 3 in Supple-
ment 1). All HRs that associated secondary outcomes with
single systolic (P < .001) or diastolic (P ≤ .02) BP indexeswere
significant (Table2; eTable5 inSupplement 1). Findings for the
secondaryoutcomeswere consistentwith those for the copri-
mary outcomes (Table 2 and Table 3 for systolic BP; eTables 5
and 6 for diastolic BP in Supplement 1). In models including
both 24-hour and nighttime BP measures, secondary out-
comesweresignificantlyassociatedwithnighttimeBP,whereas
for24-hourBPsignificancewasonly retainedforstroke (Table2
for systolic BP; eTable 5 for diastolic BP in Supplement 1; HRs
for systolic/diastolic 24-hour BP was 1.36 [95% CI, 1.14-1.63]/
1.24 [1.06-1.44]). Sensitivity analyses were confirmatory
(eTables 7-11 in Supplement 1). Heat maps for the secondary
outcomes and results for improvement in model perfor-
mance appear in Figure 1 and eTables 12 and 14 for systolic BP
and in eFigure 1 and eTables 13 and 15 for diastolic BP. Analy-
ses of the secondaryoutcomes (eFigure 2 in Supplement 1) ac-
cording to dipping status produced results comparable with
those of the primary outcomes (Figure 2).
Discussion
In this population-based cohort study, higher 24-hour and
higher nighttime BP, compared with other BP indexes, were
associated with greater risk of all-causemortality and a com-
posite cardiovascular outcome. These associations remained
significant after adjusting for conventional andautomatedof-
fice BP and after adjusting for the daytime BP and dipping ra-
tioor status.These findingswerealso largelyconsistent for sec-
ondary outcomes and in sensitivity analyses performed to
evaluate the influence of antihypertensive drug treatment at
baseline, the use of fixed clock-time intervals vs the diary
method to define day and night, and the weight of different
cohorts in the overall pooled results.
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Figure 1. HeatMaps Depicting 10-Year Risk in Relation to 24-Hour and Nighttime Systolic Blood Pressure in 11 135 Study Participants
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Derived by Cox proportional hazards regression with 24-hour and nighttime
systolic blood pressure (BP) analyzed as continuous variables. Estimates
of 10-year risk were standardized to the average of the distributions in the
whole study population (mean or ratio) of all covariables. Numbers in
the panel A grid represent the percentage of participants within each
systolic BP cross-classification category; numbers in the other grids represent
the 10-year risk.
See the Results section for P values along horizontal and vertical axes. Risks of
total mortality, cardiovascular mortality, and a coronary event were not
significantly associated with 24-hour systolic BP (P  .06).
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Over the past 30 years, ambulatory BPmonitoring devel-
oped intotherecommendedtechniqueforBPmeasurement.3,19
The current population-based study confirmed previous re-
search, indicating that ambulatoryBPmonitoringover andbe-
yondmeasures taken inclinicians’ offices improved risk strati-
fication among patients with7,8 or those suspected of having
hypertension.9 It strengthened the notion that nighttime BP
measures carry valuable prognostic information.7-9 A meta-
analysis of both summary statistics and individual-level data,
combined studies involving patients with hypertension
(n = 23856) separately fromthoseof individuals randomly re-
cruited from populations (n = 9641).26 In both patients and
populations, in analyses inwhich nighttimeBPwas addition-
ally adjusted for daytimeBP, andvice versa, nighttimeBPwas
a stronger predictor thanwas daytime BP.26With adjustment
for the 24-hour BP, both the dipping ratio and dipping status
Figure 2. Cumulative Incidence of Total Mortality and the Composite Cardiovascular Outcomes by Dipping Status
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remained significantly associated with outcome, but as evi-
dencedby the generalizedR2 statistic and in linewith the cur-
rent findings added less than 0.6% to the model fit over and
beyond the24-hourBP readings.26 Poor reproducibility of the
dipping status, intermediate reproducibility of thedipping ra-
tio, and high reproducibility of the nighttime BP might ex-
plain the statistically significantly higher predictive value of
the nighttime BP.12,13 Possible explanations for the accuracy
of the nighttime BP include minimization of confounding by
antihypertensive drug treatment, usually taken in the morn-
ing, the standardized conditions during sleep (supine posi-
tion and absence of movement), and the prognostic value of
the basal BP in sedated conditions.27
Model performance in the current studywas evaluatedby
change in the AUC. This metric is not very sensitive in model
comparisons28 if thebasicmodelperformswell, aswas thecase
in the current study, for which the AUC of the basic model
ranged from nearly 0.83 to 0.88 (eTables 12 and 13 in Supple-
ment 1). The prevailing perception among experts is that BP
is the strongest modifiable cardiovascular risk factor.29 The
small increments in change in the AUC challenge this con-
cept. Thus, an important issue in the evaluation of an addi-
tional risk prediction marker is how to interpret a small AUC
increase,whichmany researchers believe is an imprecisemet-
ric because it increases only slightly with the introduction of
an additional marker inmultivariable-adjustedmodels, even
if themarker under study carries great risk, as reflectedby the
odds ratio (or HR).30
Limitations
This study has several limitations. First, the diary approach is
thegold standard fordetermining theBP level duringwakeful-
ness and sleep.19 However, the analyses based on short clock-
time intervals16 or confined to7133 individuals (64.1%)withdi-
ary informationwereconfirmatory.Moreover, theseshort fixed
clock-timeintervalseliminatethetransitionperiodsinthemorn-
ing andeveningwhenBPchanges rapidly, resulting indaytime
andnighttimeBPlevels thatarewithin1to2mmHgoftheawake
and asleep levels.16 Second, antihypertensive drug treatment
was only recorded at baseline and could therefore not be ad-
justed for as a time-dependent covariable. However, initiation
of BP-lowering treatment during follow-up is more likely to
weakenratherthantostrengthentheassociationsbetweenbase-
line BP andoutcomes.7 Third, theremight bemisclassification
bias in theassessmentof thecardiovascular studyendpoints.31
However, all-cause mortality does not require any adjudica-
tion, as vital status only involves checking population regis-
tries.Therewasconsistencybetweenthe findings for totalmor-
tality, thecompositecardiovascularoutcomeandthesecondary
outcomes.Fourth, amongsomeparticipants,nighttimeBPwas
the time-weightedaverageofonly3 readings,which is less than
proposedbyguidelines.19However, a recent analysis17 demon-
strated that 6 daytime and 3 nighttime readings are sufficient
in large studies to estimate the BP level, to reproducibly cross-
classify individualsbasedontheirofficeandambulatoryBP,and
to preserve the association with adverse health outcomes.
Conclusions
Inthispopulation-basedcohortstudy,higher24-hourandnight-
timeBPweresignificantlyassociatedwithgreater risksofdeath
and a composite cardiovascular outcome, even after adjusting
for other office-based or ambulatory blood pressuremeasure-
ments.Thus,24-hourandnighttimebloodpressuremaybecon-
sidered optimal measurements for estimating cardiovascular
risk, althoughstatistically,model improvementcomparedwith
other blood pressure indexes was small.
ARTICLE INFORMATION
Accepted for Publication: June 18, 2019.
Author Affiliations: Studies Coordinating Centre,
Research Unit Hypertension and Cardiovascular
Epidemiology, KU Leuven Department of
Cardiovascular Sciences, University of Leuven,
Leuven, Belgium (Yang, Thijs, Zhang, Wei,
Staessen); Department of Cardiology, Shanghai
General Hospital, Shanghai Jiao Tong University
School of Medicine, Shanghai, China (Yang, Zhang);
Laboratorio de Neurociencias and Instituto
Cardiovascular, Universidad del Zulia, Maracaibo,
Venezuela (Melgarejo, Maestre); Centro de
Nefrología and Departamento de Fisiopatología,
Hospital de Clínicas, Universidad de la República,
Montevideo, Uruguay (Boggia); The Steno Diabetes
Center Copenhagen, Gentofte, and Center for
Health, Capital Region of Denmark, Copenhagen,
Denmark (Hansen); Tohoku Institute for
Management of Blood Pressure, Sendai, Japan
(Asayama, Ohkubo, Imai); Department of Hygiene
and Public Health, Teikyo University School of
Medicine, Tokyo, Japan (Asayama, Ohkubo);
Department of Medicine, Glostrup Hospital,
University of Copenhagen, Copenhagen, Denmark
(Jeppesen); Cambridge University Hospitals,
Addenbrook’s Hospital, Cambridge, United
Kingdom (Dolan); The First Department of
Cardiology, Interventional Electrocardiology and
Hypertension, Jagiellonian University Medical
College, Krakow, Poland (Stolarz-Skrzypek,
Kawecka-Jaszcz); Institute of Internal and
Preventive Medicine and Institute of Cytology and
Genetics, Siberian Branch of the Russian Academy
of Sciences, Novosibirsk, Russian Federation
(Malyutina); Department of Medicine, University of
Padua, Padua, Italy (Casiglia); Section of Geriatrics,
Department of Public Health and Caring Sciences,
Uppsala University, Uppsala, Sweden (Lind); Faculty
of Medicine, Charles University, Pilsen, Czech
Republic (Filipovský); Department of Biomedical
Sciences, Division of Neuroscience and Department
of Human Genetics, University of Texas Rio Grande
Valley School of Medicine, Brownsville (Maestre);
Center for Epidemiological Studies and Clinical
Trials and Center for Vascular Evaluation, Shanghai
Institute of Hypertension, Ruijin Hospital, Shanghai
Jiao Tong University School of Medicine, Shanghai,
China (Li, Wang); Asociación Española Primera en
Salud, Montevideo, Uruguay (Sandoya);
Hypertension Unit, Department of Hypertension
and Diabetology, Medical University of Gdańsk,
Gdańsk, Poland (Narkiewicz); Conway Institute of
Biomolecular and Biomedical Research, University
College Dublin, Dublin, Ireland (O’Brien); Centre for
Molecular and Vascular Biology, KU Leuven
Department of Cardiovascular Sciences, University
of Leuven, Leuven, Belgium (Verhamme);
Cardiovascular Research Institute Maastricht
(CARIM), Maastricht University, Maastricht,
the Netherlands (Staessen).
Author Contributions:Dr Staessen had full access
to the data in the study and takes responsibility for
the integrity of the data and the accuracy of the
data analysis.
Concept and design: Yang, Hansen, Jeppesen,
Filipovský, Sandoya, O'Brien, Staessen.
Acquisition, analysis, or interpretation of data: Yang,
Melgarejo, Thijs, Zhang, Boggia, Wei, Asayama,
Ohkubo, Dolan, Stolarz-Skrzypek, Malyutina,
Casiglia, Lind, Filipovský, Maestre, Li, Wang, Imai,
Kawecka-Jaszcz, Sandoya, Narkiewicz, Verhamme,
Staessen.
Drafting of the manuscript: Yang, Melgarejo,
Sandoya, O'Brien, Staessen.
Critical revision of the manuscript for important
intellectual content: All authors.
Statistical analysis: Yang, Melgarejo, Thijs, Wei, Li,
Staessen.
Obtained funding: Asayama, Ohkubo, Jeppesen,
Casiglia, Maestre, Li, Wang, Narkiewicz, Verhamme,
Staessen.
Research Original Investigation Association of Office and Ambulatory Blood PressureWith Mortality and CV Outcomes
418 JAMA August 6, 2019 Volume 322, Number 5 (Reprinted) jama.com
© 2019 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a University of Texas - Rio Grande Valley User  on 02/04/2020
Administrative, technical, or material support:Wei,
Ohkubo, Stolarz-Skrzypek, Malyutina, Casiglia, Lind,
Maestre, Li, Imai, Sandoya, Narkiewicz, Staessen.
Supervision: Asayama, Ohkubo, Casiglia, Filipovský,
Maestre, Imai, Kawecka-Jaszcz, O'Brien,
Verhamme, Staessen.
Conflict of Interest Disclosures:Dr Narkiewicz
reported receiving lecture fees from Servier, Krka
Pharma, Berlin-Chemie/Menarini, Egis, Sandoz,
Idorsia, Medtronic, Mylan, Polpharma, Adamed,
and Gedeon Richer. No other disclosures were
reported.
Funding/Support: Belgium: grants
HEALTH-F7-305507 HOMAGE from the European
Union; advanced researcher grant
2011-294713-EPLORE and proof-of-concept grant
713601-uPROPHET from the European Research
Council, JTC2017-046-PROACT from the European
Research Area Net for Cardiovascular Diseases; and
G.0881.13 from the Research Foundation Flanders,
Ministry of the Flemish Community, Brussels,
Belgium; China: grants 81170245, 81270373,
81470533, and 91639203 from the National Natural
Science Foundation of China; 2013CB530700 from
theMinistry of Science and Technology; 1012 from
the China-European Union Collaboration, Beijing,
China; 14ZR1436200 and 15XD1503200 from the
Shanghai Commission of Science and Technology;
and 20152503 from the Gaofeng Clinical Medicine
Education; Czech Republic: LSHM-CT-2006–
037093 and HEALTH-F4-2007-201550 from the
European Union and P36 from Charles University
research fund project; Denmark:01-2-9-9A-22914
from the Danish Heart Foundation and R32-A2740
from the Lundbeck Fonden; Ireland: the Irish Allied
Bank; Italy: LSHM-CT-2006-037093 and
HEALTH-F4-2007-201550 from the European
Union; Japan: 16H05243, 16H05263, 16K09472,
16K11850, 16K15359, 17H04126, 17H06533,
17K15853, 17K19930, 18K09674, 18K09904, and
18K17396 from theMinistry of Culture, Sports,
Science and Technology; grant-in-aid H28-4 for
young scientists of Showa Pharmaceutical
University, Japan Atherosclerosis Prevention Fund
(comprehensive research on cardiovascular and
lifestyle related diseases); H26-Junkankitou
(Seisaku)-Ippan-001 and
H29-Junkankitou-Ippan-003 from theMinistry of
Health, Labor, andWelfare; NouEi 2-02 from the
Ministry of Agriculture, Forestry and Fisheries;
Academic Contributions from Pfizer Japan Inc; and
scholarship donations from Chugai Pharmaceutical
Company and Daiichi Sankyo Co; Poland (Gdańsk):
LSHM-CT-2006-037093 and
HEALTH-F4-2007-201550 from the European
Union; Poland (Kraków): LSHM-CT-2006-037093
and HEALTH-F4-2007-201550 from the European
Union and Foundation for Polish Science; Russian
Federation: LSHM-CT-2006–037093 and
HEALTH-F4-2007–201550 from the European
Union; Uruguay: Asociación Española Primera en
Salud; Venezuela: 1-R01AG036469 A1 from the US
National Institute of Aging and the Fogarty
International Center, 1-R03 AG054186-01 from the
US National Institutes of Health and National
Institute of Aging; FONACIT, G-97000726 from
Caracas; and LOCTI/008-2008 from
FundaConCiencia, Maracaibo.
Role of the Funder/Sponsor: The funders had no
role in the design and conduct of the study;
collection, management, analysis, and
interpretation of the data; preparation, review, or
approval of themanuscript; and decision to submit
themanuscript for publication.
IDACO Investigators: Belgium: B. Mujaj,
N. Cauwenberghs, T. Kuznetsova, L. Thijs,
J. A. Staessen, F.-F. Wei, W.-Y. Yang, C.-G. Yu, and
Z.-Y. Zhang; China: Y. Li, C.-S. Sheng, Q.-F. Huang,
and J.-G. Wang; The Czech Republic: J. Filipovský,
J. Seidlerová, andM. Tichá; Denmark: T. W. Hansen,
H. Ibsen, J. Jeppesen, S. Rasmussen, and
C. Torp-Pedersen; Ireland: E. Dolan and E. O’Brien;
Italy: E. Casiglia, A. Pizzioli, and V. Tikhonoff; Japan:
K. Asayama, J. Hashimoto, H. Hoshi, Y. Imai,
R. Inoue, M. Kikuya, H. Metoki, T. Obara, T. Ohkubo,
H. Satoh, and K. Totsune; Poland (Gdańsk):
N. Gilis-Malinowska and K. Narkiewicz; Poland
(Kraków): A. Adamkiewicz-Piejko, M. Cwynar,
J. Gąsowski, T. Grodzicki, K. Kawecka-Jaszcz,
W. Lubaszewski, A. Olszanecka,
K. Stolarz-Skrzypek, B. Wizner, W.Wojciechowska,
and J. Zyczkowska; The Russian Federation:
T. Kuznetsova, S. Malyutina, Y. Nikitin, E. Pello,
G. Simonova, andM. Voevoda; Sweden: B. Andrén,
L. Berglund, K. Björklund-Bodegård, L. Lind, and
B. Zethelius; Uruguay:M. Bianchi, J. Boggia,
V. Moreira, E. Sandoya, C. Schettini, E. Schwedt,
and H. Senra; Venezuela: G. Maestre and
J. D. Melgarejo.
Meeting Presentations: Part of the results
was presented at scientific meetings of the
European Society of Cardiology, August 25-30,
2018, Munich, Germany, and of the International
Society of Hypertension, September 20-23, 2018,
Beijing, China.
Additional Contributions:We thank
V. De Leebeeck, MSc, and R. Wolfs, BSc,
Studies Coordinating Centre, Research Unit
Hypertension and Cardiovascular Epidemiology,
KU Leuven Department of Cardiovascular Sciences,
University of Leuven, Leuven, Belgium, for clerical
assistance. They received a salary from the
University of Leuven, but no additional
compensation for this work.
Data Sharing Statement: See Supplement 2.
REFERENCES
1. Leung AA, Nerenberg K, Daskalopoulou SS, et al;
CHEP Guidelines Task Force. Hypertension
Canada’s 2016 Canadian Hypertension Education
Program guidelines for blood pressure
measurement, diagnosis, assessment of risk,
prevention, and treatment of hypertension. Can J
Cardiol. 2016;32(5):569-588. doi:10.1016/j.cjca.2016.
02.066
2. Whelton PK, Carey RM, AronowWS, et al. 2017
ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/
NMA/PCNA guideline for prevention, detection,
evaluation, andmanagement of high blood
pressure in adults: a report of the American College
of Cardiology/American Heart Association Task
Force on Clinical Practice Guidelines. J AmColl Cardiol.
2018;71(19):e127-e248. doi:10.1016/j.jacc.2017.11.006
3. National Institute for Health and Clinical
Excellence (NICE). Hypertension in adults:
diagnosis andmanagement. http://www.nice.org.
uk/guidance/CG127. Published August 2011.
Updated November 2016. Accessed June 3, 2019.
4. Williams B, Mancia G, SpieringW, et al; ESC
Scientific Document Group. 2018 ESC/ESH
Guidelines for themanagement of arterial
hypertension. Eur Heart J. 2018;39(33):3021-3104.
doi:10.1093/eurheartj/ehy339
5. Shimamoto K, Ando K, Fujita T, et al; Japanese
Society of Hypertension Committee for Guidelines
for theManagement of Hypertension. The
Japanese Society of Hypertension guidelines for
themanagement of hypertension (JSH 2014).
Hypertens Res. 2014;37(4):253-390. doi:10.1038/
hr.2014.20
6. Liu LS. Writing Group of 2010 Chinese guidelines
for themanagement of hypertension. 2010 Chinese
guidelines for themanagement of hypertension [in
Chinese]. Chin J Hypertens. 2011;19(8):701-742.
7. Staessen JA, Thijs L, Fagard R, et al; Systolic
Hypertension in Europe Trial Investigators.
Predicting cardiovascular risk using conventional vs
ambulatory blood pressure in older patients with
systolic hypertension. JAMA. 1999;282(6):539-546.
doi:10.1001/jama.282.6.539
8. Dolan E, Stanton A, Thijs L, et al. Superiority of
ambulatory over clinic blood pressure
measurement in predicting mortality: the Dublin
outcome study.Hypertension. 2005;46(1):156-161.
doi:10.1161/01.HYP.0000170138.56903.7a
9. Ben-Dov IZ, Kark JD, Ben-Ishay D, Mekler J,
Ben-Arie L, BursztynM. Predictors of all-cause
mortality in clinical ambulatory monitoring: unique
aspects of blood pressure during sleep.Hypertension.
2007;49(6):1235-1241. doi:10.1161/
HYPERTENSIONAHA.107.087262
10. Myers MG, Valdivieso M, Kiss A. Use of
automated office blood pressure measurement to
reduce the white coat response. J Hypertens.
2009;27(2):280-286. doi:10.1097/HJH.
0b013e32831b9e6b
11. O’Brien E, Sheridan J, O’Malley K. Dippers and
non-dippers. Lancet. 1988;2(8607):397. doi:10.
1016/S0140-6736(88)92867-X
12. Hernández-del Rey R, Martin-Baranera M,
Sobrino J, et al; Spanish Society of Hypertension
Ambulatory Blood Pressure Monitoring Registry
Investigators. Reproducibility of the circadian blood
pressure pattern in 24-h versus 48-h recordings:
the Spanish Ambulatory Blood Pressure Monitoring
Registry. J Hypertens. 2007;25(12):2406-2412. doi:
10.1097/HJH.0b013e3282effed1
13. McGowan NJ, Gough K, Padfield PL. Nocturnal
dipping is reproducible in the long term. Blood Press
Monit. 2009;14(5):185-189. doi:10.1097/MBP.
0b013e32832ff4e1
14. Thijs L, Hansen TW, KikuyaM, et al; IDACO
Investigators. The International Database of
Ambulatory Blood Pressure in relation to
Cardiovascular Outcome (IDACO): protocol and
research perspectives. Blood Press Monit. 2007;12
(4):255-262. doi:10.1097/MBP.0b013e3280f813bc
15. World Medical Association. World Medical
Association Declaration of Helsinki: ethical
principles for medical research involving human
subjects. JAMA. 2013;310(20):2191-2194. doi:10.
1001/jama.2013.281053
16. Fagard R, Brguljan J, Thijs L, Staessen J.
Prediction of the actual awake and asleep blood
pressures by various methods of 24 h pressure
analysis. J Hypertens. 1996;14(5):557-563. doi:10.
1097/00004872-199605000-00003
17. YangWY, Thijs L, Zhang ZY, et al; International
Database; on Ambulatory blood pressure in relation
to Cardiovascular Outcomes (IDACO) Investigators.
Evidence-based proposal for the number of
ambulatory readings required for assessing blood
Association of Office and Ambulatory Blood PressureWith Mortality and CV Outcomes Original Investigation Research
jama.com (Reprinted) JAMA August 6, 2019 Volume 322, Number 5 419
© 2019 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a University of Texas - Rio Grande Valley User  on 02/04/2020
pressure level in research settings: an analysis of
the IDACO database. Blood Press. 2018;27(6):341-
350. doi:10.1080/08037051.2018.1476057
18. Franklin SS, LarsonMG, Khan SA, et al. Does the
relation of blood pressure to coronary heart disease
risk change with aging? the FraminghamHeart
Study. Circulation. 2001;103(9):1245-1249. doi:10.
1161/01.CIR.103.9.1245
19. O’Brien E, Parati G, Stergiou G, et al; European
Society of HypertensionWorking Group on Blood
Pressure Monitoring. European Society of
Hypertension position paper on ambulatory blood
pressure monitoring. J Hypertens. 2013;31(9):
1731-1768. doi:10.1097/HJH.0b013e328363e964
20. Hansen TW, Jeppesen J, Rasmussen S, Ibsen H,
Torp-Pedersen C. Ambulatory blood pressure
monitoring and risk of cardiovascular disease:
a population based study. Am J Hypertens. 2006;19
(3):243-250. doi:10.1016/j.amjhyper.2005.09.018
21. Ingelsson E, Björklund-Bodegård K, Lind L,
Arnlöv J, Sundström J. Diurnal blood pressure
pattern and risk of congestive heart failure. JAMA.
2006;295(24):2859-2866. doi:10.1001/jama.295.
24.2859
22. Pencina MJ, D’Agostino RB, Zdrojewski T, et al.
Apolipoprotein B improves risk assessment of
future coronary heart disease in the Framingham
Heart Study beyond LDL-C and non-HDL-C. Eur J
Prev Cardiol. 2015;22(10):1321-1327. doi:10.1177/
2047487315569411
23. Kuznetsova T, Staessen JA, Kawecka-Jaszcz K,
et al. Quality control of the blood pressure
phenotype in the European Project on Genes in
Hypertension.Blood PressMonit. 2002;7(4):215-224.
doi:10.1097/00126097-200208000-00003
24. Hosmer DW Jr, Lemeshow S. Applied Logistic
Regression. New York, NY: JohnWiley & Sons; 1989:
47-56.
25. Nyholt DR. Genetic case-control association
studies—correcting for multiple testing.HumGenet.
2001;109(5):564-567. doi:10.1007/s00439-001-
0611-4
26. Hansen TW, Li Y, Boggia J, Thijs L, Richart T,
Staessen JA. Predictive role of the nighttime blood
pressure.Hypertension. 2011;57(1):3-10. doi:10.1161/
HYPERTENSIONAHA.109.133900
27. Smirk FH. Observations onmortality of 270
treated and 199 untreated retinal grade I and II
hypertensive patients followed in all instances for
5 years. N ZMed J. 1964;63:413-443.
28. Cook NR. Use andmisuse of the receiver
operating characteristic curve in risk prediction.
Circulation. 2007;115(7):928-935. doi:10.1161/
CIRCULATIONAHA.106.672402
29. Murray CJL, Ezzati M, Flaxman AD, et al.
GBD 2010: design, definitions, andmetrics. Lancet.
2012;380(9859):2063-2066. doi:10.1016/S0140-
6736(12)61899-6
30. Baker SG, Schuit E, Steyerberg EW, et al. How
to interpret a small increase in AUCwith an
additional risk predictionmarker: decision analysis
comes through. Stat Med. 2014;33(22):3946-3959.
doi:10.1002/sim.6195
31. MienoMN, Tanaka N, Arai T, et al. Accuracy of
death certificates and assessment of factors for
misclassification of underlying cause of death.
J Epidemiol. 2016;26(4):191-198. doi:10.2188/jea.
JE20150010
Editor's Note
Effective Use of Ambulatory Blood PressureMonitoring
Philip Greenland, MD
For almost 100 years, higher levels of blood pressure (BP)
have been recognized as critically important risk factors
for clinical disorders of the cardiovascular systems, brain,
and kidney.1 With numerous effective lifestyle and drug
treatments available and
with cl inical tr ia ls that
convincingly showed the
benefits of BP lowering in
appropriately selected patients, it is now widely recom-
mended that BP measurement be a routine part of general
health screening.1-6 Evidence favoring the use of ambula-
tory BP monitoring (ABPM) for measurement of BP has
accumulated and guidelines now refer to ABPM as the “best
out-of-office measurement method.”1 In addition, the Cen-
ters for Medicare & Medicaid Services (CMS) recently pro-
posed to pay for expanded use of ABPM for detection of sus-
pected “white coat” hypertension and detection of masked
hypertension.7
Ambulatory BP monitoring is used to obtain out-of-
office BP readings at established intervals, usually every 15
to 30 minutes over a period of at least 24 hours. A system-
atic review conducted by the US Preventive Services Task
Force8 concluded that ABPM provided a better method to
predict long-term cardiovascular disease outcomes than did
office BP measurements. Therefore, as described in the
article by Yang and colleagues,9 ABPM is considered a pre-
ferred method for BP assessment in North American, Euro-
pean, Japanese, and Chinese guidelines.1-6 However,
because ABPM monitoring generates a much larger volume
of data than other types of BP measurement, including
nighttime BPmeasurements, it has been uncertain which BP
index, or indexes, are more strongly associated with adverse
health outcomes. The goal of the study by Yang et al9 was to
examine data from numerous sources to address this clini-
cally important question.
Using a rigorous assessment of ABPM in more than
11000 adults, higher 24-hour and nighttime BP were signifi-
cantly associated with greater risks of death and a cardiovas-
cular outcome, consisting of cardiovascular mortality com-
bined with nonfatal coronary events, heart failure, and
stroke. The association persisted after adjusting for other
office-based or ambulatory monitoring–derived BP measure-
ments, all of which were also associated with the adverse
outcomes. This is important information for patients and cli-
nicians as they determine how to use the large amount of BP
data from ABPM. Based on these findings, it is reasonable to
consider the 2 most clinically relevant measurements from
ABPM to be the 24-hour BP and the nighttime BP. Either
could be used to justify treatment of BP that is above the
treatment threshold. Most important is to obtain accurate
measurement from every patient and to initiate and monitor
treatment when indicated.
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